Monthly Glp1 Progress Check In What To Measure

A monthly GLP-1 progress check-in gives you a clear snapshot of how your treatment is working. Weekly weigh-ins and daily logging are useful, but a dedicated monthly review helps you zoom out and see real trends. It also prepares you for productive conversations with your healthcare provider.

Key Takeaways: - The Monthly Check-In Checklist - Learn how to interpret your monthly numbers - Health Markers to Review Quarterly - Non-Scale Victories to Document Monthly - When to Contact Your Provider Between Check-Ins

This guide walks you through exactly what to measure each month, how to interpret your numbers, and when to reach out to your provider about adjustments.

The Monthly Check-In Checklist

Set aside 15 to 20 minutes once a month for your check-in. Pick the same day each month, like the first Saturday. Here is what to review.

Body measurements. Take your waist, hips, chest, upper arms, and thighs using a flexible tape measure. Compare these to last month. Even small changes of half an inch matter over time. Your waist circumference is especially important because it reflects visceral fat, which is the most metabolically dangerous type.

Weight trend. Look at your weekly weigh-ins from the past month. Calculate your average. Compare this month's average to last month's average. This smooths out daily fluctuations and shows you the real direction you're heading.

Progress photos. Take a front, side, and back photo in the same clothing and lighting as last month. You may not notice gradual changes in the mirror, but side-by-side photos tell a different story.

Side effect review. Look back at your . Are symptoms improving, stable, or getting worse? Have any new ones appeared? This information helps your provider decide whether to adjust your dose.

---

Free Download: GLP-1 Progress Report Template A structured monthly check-in sheet with space for all your key metrics. Print it out or fill it in digitally. Get yours free) we'll email it to you instantly.

[Download CTA Button]

---

"Compounding pharmacies serve a critical role in healthcare, but patients need to understand the difference between a properly regulated 503B facility and an unregulated operation. Ask about PCAB accreditation and third-party testing.", Dr. Scott Brunner, PharmD, Alliance for Pharmacy Compounding

How to Interpret Your Monthly Numbers

Raw numbers mean nothing without context. Here is how to make sense of what you see.

View data table

Bar chart showing lifestyle factors impact on glp-1 results: Protein Intake (90), Exercise (85), Sleep Quality (78), Hydration (72), Stress Mgmt (65)

Category	Impact on Treatment Outcomes (%)	Detail
Protein Intake	90	Preserves muscle mass
Exercise	85	Enhances weight loss
Sleep Quality	78	Supports metabolism
Hydration	72	Reduces side effects
Stress Mgmt	65	Cortisol reduction

Weight loss pace. Clinical trials for GLP-1 medications show average weight loss of 1 to 2 pounds per week during the first several months. But averages hide wide individual variation. Some months you might lose 6 pounds. Other months, just 1 or 2. Both are normal.

If your weight hasn't changed in 4 or more weeks and you're following your nutrition plan, it may be time to discuss a dose adjustment with your provider. Plateaus lasting 2 to 3 weeks are typical and usually resolve on their own.

Measurement changes without weight changes. If your waist is shrinking but the scale isn't moving, you're likely losing fat and maintaining muscle. This is a positive outcome, especially if you're strength training. Body recomposition is a real phenomenon on GLP-1 treatment.

Side effect trends. Most GLP-1 side effects peak during the first 2 to 4 weeks after starting or increasing a dose. They typically improve as your body adjusts. If side effects are getting worse over time rather than better, flag this with your provider.

Learn more about what to expect at each stage in our .

Health Markers to Review Quarterly

Some metrics don't change fast enough to check monthly. Add these to your quarterly review, ideally timed with lab work.

Blood sugar markers. HbA1c reflects your average blood sugar over 3 months. Fasting glucose shows your current baseline. GLP-1 medications can improve both, sometimes significantly. Even people without diabetes often see improvements in insulin sensitivity.

Cholesterol panel. LDL, HDL, and triglycerides may all improve with GLP-1 treatment and weight loss. Track these numbers over time to see the trend.

Blood pressure. Many GLP-1 users see blood pressure improvements within the first few months. If you monitor at home, include your average reading in your check-in.

Liver enzymes. ALT and AST can improve as visceral fat decreases. Your provider may order these as part of routine monitoring.

Share all of these markers with your for a complete picture of your health trajectory.

Non-Scale Victories to Document Monthly

Numbers don't capture everything. Each month, write down 3 to 5 non-scale victories. These are the real-life improvements that make GLP-1 treatment worthwhile.

Physical changes: - Clothes fitting differently - More stamina during walks or workouts - Less joint pain - Better sleep

Mental and emotional changes: - Reduced food noise and fewer cravings - Less anxiety around meals - Improved body confidence - More energy and motivation

Health behavior changes: - Consistently hitting protein targets - Regular exercise habits - Better hydration - Taking medication on schedule

When you hit a plateau, reading through your accumulated non-scale victories reminds you that progress is happening on many fronts. The lets you log these wins alongside your other data for a complete monthly view.

When to Contact Your Provider Between Check-Ins

Most monthly check-ins are for your own reference. But certain findings should prompt a conversation with your healthcare provider before your next scheduled appointment.

Reach out if you notice: - Weight gain of 5 or more pounds that persists for 2 weeks - Side effects that are worsening rather than improving - New symptoms like severe abdominal pain, persistent vomiting, or vision changes - No weight loss for 6 or more consecutive weeks despite following your plan - Difficulty eating enough calories or protein

Your tracking data makes these conversations more productive. Instead of guessing, you can share specific dates, symptoms, and patterns. This helps your provider make faster, better-informed decisions about your .

Frequently Asked Questions

How much weight should I expect to lose each month on GLP-1?

Average monthly weight loss varies widely. Clinical data suggests 4 to 8 pounds per month during the titration phase, though some months may be more and others less. Weight loss typically slows after the first 6 months. Focus on your overall trend rather than any single month.

What if my measurements aren't changing?

If neither weight nor measurements have changed in 6 or more weeks, discuss this with your provider. They may recommend a dose adjustment, review your nutrition plan, or check for other factors. Sometimes a small change in protein intake or activity level can restart progress.

Should I do my monthly check-in on a specific day?

Pick any consistent day that works for your schedule. Many people choose the first weekend of each month. The key is consistency so that your comparisons are meaningful. Avoid checking right after a holiday or special event when water retention might skew your numbers.

How long should I continue monthly check-ins?

Continue monthly check-ins for as long as you're on GLP-1 medication and ideally beyond. During maintenance, monthly reviews help you catch weight regain early and stay on top of your health markers. Many people find that the habit of regular self-monitoring helps them maintain their results long term.

Let's Make This Happen

The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide) no pressure, no commitment.

---

Medical References

1. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
2. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
3. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
4. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
5. Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
6. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]

Sources &. References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2^[1] (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3^[2] (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5^[3] (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2^[4] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
8. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3^[5] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
9. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4^[6] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
11. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
12. Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816

The information in this article is intended for educational use only and shouldn't be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.

Last updated: 2026-03-24